EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound

Patricia Resa-Infante, Patricia Piñol, Fernando Laguía, Gerard Campos-Gonzalez, Àlex Cobos, Victor Urrea, Maria Del Carmen Garcia-Guerrero, Yaiza Rosales-Salgado, Marina Cid, Jorge Díaz-Pedroza, Leonard D Shultz, Voot Yin und 4 weitere

Translational Research · 2026

DOI: 10.1016/j.trsl.2026.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Patricia Resa-Infante und 15 weiteren Autor:innen. Beteiligte Einrichtung: IrsiCaixa, 08916, Badalona, Barcelona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), 08500, Vic, Spain; Germans Trias i Pujol …. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, fms-Like Tyrosine Kinase 3. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Carlos III Health Institute, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in antiretroviral therapy (ART), HIV-1 cure efforts remain hindered by viral persistence in long-lived myeloid cells and immune-privileged tissues that are poorly accessible and therefore unlikely to be assessed in human clinical trials. Consequently, robust research platforms, such as immune-cell humanized mice, are needed to bridge preclinical and clinical HIV research. However, previously described humanized mouse models often show incomplete hematopoietic development, particularly showing low levels of NK or myeloid cells. Herein, we evaluate a humanized FLT3 mouse model that develops NK cells, myeloid progenitors, monocytes, and both conventional (cDCs) and plasmacytoid dendritic cells (pDCs), and assessed its capacity to support HIV-1 infection, persistence, and viral rebound. Human cord blood derived CD34+ hematopoietic stem cells (HSC) were engrafted in FLT3 (Hu-FLT3) and NSG (Hu-NSG) mouse strains for comparison. While Hu-NSG and Hu-FLT3 mice showed comparable human lymphocyte levels, the proportion of myeloid-enriched populations, including monocytes, pDCs and cDCs, was three-fold higher in Hu-FLT3 mice (16.2%) than in Hu-NSG mice (5.6%), and the proportion of NK cells was six-fold higher (12.8% vs. 1.9%). Both strains supported HIV-1 infection, maintained viral replication for 17 weeks in untreated animals, and had detectable proviral DNA in peripheral blood, bone marrow and spleen. Oral ART reduced plasma HIV-1 RNA to undetectable levels within four weeks in both strains. After treatment discontinuation, viral rebound occurred within three weeks and approached pre-ART levels, consistent with rebound kinetics observed after treatment interruption in people living with HIV (PLWH). Human immune cells and HIV-1 RNA were more abundant in tissues from Hu-FLT3 mice than in Hu-NSG mice. This study establishes Hu‑FLT3 mice as a novel, robust and accessible in vivo platform to investigate potential HIV cure and persistence‑targeting interventions with translational relevance to human therapeutic development thanks to the improved and more complete human immune repertoire in Hu-FLT3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV Infectionsfms-Like Tyrosine Kinase 3AnimalsHumansMiceHematopoietic Stem Cell TransplantationHematopoietic Stem CellsDendritic Cells

Stichwörter der Autor:innen

HIV‑1 infectionHumanized mouse modelInnate immune reconstitutionPreclinical translational modelTissue reservoirsViral persistence

Substanzen

fms-Like Tyrosine Kinase 3

Autor:innen und Institutionen

  • IrsiCaixa, 08916, Badalona, Barcelona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), 08500, Vic, Spain; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, 08916, Badalona, Spain; CI…
  • IrsiCaixa, 08916, Badalona, Barcelona, Spain.
  • Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), 08193, Bellaterra, Spain; IRTA Programa de Sanitat Animal, Centr…
  • Comparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916, Badalona, Spain.
  • The Jackson Laboratory, ME, 04609, Bar Harbor, United States.
  • Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, MA, 01605, Worcester, United States.

Förderung

  • NIH HHS
  • Carlos III Health Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Foundation for the National Institutes of Health
  • Department of Health
  • España Ministerio de Ciencia e Innovación
  • Grifols

Zitieren

APA

Resa-Infante, P., Piñol, P., Laguía, F., Campos-Gonzalez, G., Cobos, À., Urrea, V., Garcia-Guerrero, M. D. C., Rosales-Salgado, Y., Cid, M., Díaz-Pedroza, J., Shultz, L. D., Yin, V., Brehm, M. A., Soper, B., Salgado, M., & Martinez-Picado, J. (2026). Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound. Translational Research. https://doi.org/10.1016/j.trsl.2026.08.004

Vancouver

Resa-Infante P, Piñol P, Laguía F, Campos-Gonzalez G, Cobos À, Urrea V, et al. Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound. Translational Research. 2026. doi:10.1016/j.trsl.2026.08.004

BibTeX
@article{ResaInfante2026,
  author = {Resa-Infante, Patricia and Piñol, Patricia and Laguía, Fernando and Campos-Gonzalez, Gerard and Cobos, Àlex and Urrea, Victor and Garcia-Guerrero, Maria Del Carmen and Rosales-Salgado, Yaiza and Cid, Marina and Díaz-Pedroza, Jorge and Shultz, Leonard D and Yin, Voot and Brehm, Michael A and Soper, Brian and Salgado, María and Martinez-Picado, Javier},
  title = {Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound},
  journal = {Translational Research},
  year = {2026},
  doi = {10.1016/j.trsl.2026.08.004}
}
Kostenlos starten →